Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and autoimmune diseases, announces that no significant differences were observed between rEV131 and placebo in the Phase IIb trial in allergic rhinitis and the primary endpoint was therefore not met.
